It is increasingly being recognized that directly targeting the aging process, as opposed to individual aging-related diseases or symptoms, is a viable strategy. This is leading to R&D with the ultimate aim of commercializing therapies directed at slowing aging itself.

Some therapeutic approaches – direct-to-consumer nutraceuticals and trial-tested scientific diets – do not require FDA approval, which can significantly reduce their time to market.

To slow the aging process, nonstandard therapies such as blood-based therapies are also being tried.

Big-data approaches are being harnessed in an attempt to build models of healthy aging.

Approaches are increasingly coming directly from aging results in model organisms.